Prévention de l'athérosclérose
et de la maladie coronarienne
Gilbert Gosselin
, M.D.
Interested in the modification of the risk
factors and by pharmaceutical prevention.
Implicated in major secondary prevention trials
(HOPE, PEACE, HOPE-TOO, ONTARGET, ORIGIN) and in the medical
treatment of stable angina pectoris with the COURAGE trial.
Heart Outcomes Prevention Evaluation Study Investigators :
Effects of an angiotensin?converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. N Engl J Med 342:
145-53, 2000.
Tardif JC, Côté G,
Lespérance J,
Gosselin G, Joyal M, deGuise P, Bilodeau L,
Doucet S, Harel F, Couturier A, Gallo R, Grégoire J,
MultiVitamins and Probucol Study Group: Impact of residual plaque
burden after balloon angioplasty in the MultiVitamins and
Probucol (MVP) trial. Can J Cardiol (1):49-55, 2001.
